<DOC>
	<DOCNO>NCT02411591</DOCNO>
	<brief_summary>This medical research evaluate safety efficacy two new medicine ( necitumumab abemaciclib ) , administer combination participant affect defined type advance lung cancer ( stage IV non-small-cell lung cancer ) .</brief_summary>
	<brief_title>A Study Necitumumab Abemaciclib Participants With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC Stage IV : Part A : NSCLC Stage IV ( type ) . Part B : NSCLC Stage IV ( squamous nonsquamous ) . Measurable disease time study entry define Response Evaluation Criteria Solid Tumors Version 1.1 ( RECIST 1.1 ) . The participant must progress platinumbased chemotherapy AND receive maximum 1 prior chemotherapy advance and/or metastatic disease OR must judge physician ineligible standard secondline chemotherapy . Prior treatment epidermal growth factor receptortyrosine kinase inhibitor ( EGFRTKI ) anaplastic lymphoma kinase ( ALK ) inhibitor mandatory participant whose tumor EGFRactivating mutation ALK translocation . Prior target agent neoadjuvant/adjuvant therapy permit exception cyclindependent kinase ( CDK ) 4/6targeting agent necitumumab . The participant tumor tissue available biomarker analysis . The participant Eastern Cooperative Oncology Group performance status score 01 . Have adequate organ function . The participant currently enrol clinical trial involve investigational product nonapproved use drug device . Prior treatment CDK4/6targeting agent necitumumab permit . Have serious concomitant systemic disorder significant cardiac disease . The participant undergone major surgery receive investigational therapy 30days prior study enrollment . The participant undergone chest irradiation within 4 week prior receive study treatment . The participant brain metastasis symptomatic . History arterial venous thromboembolism within 3 month prior study enrollment . Participants history venous thromboembolism beyond 3 month prior study enrollment enrol appropriately treat low molecular weight heparin . The participant active infection require systemic therapy . The participant know allergy / history hypersensitivity reaction treatment component , include ingredient use formulation necitumumab abemaciclib , contraindication one administer treatment . The participant pregnant breastfeeding . The participant concurrent active malignancy . Previous history malignancy permit , provide participant free disease â‰¥3 year , exception adequately treat basal squamous cell carcinoma skin , preinvasive carcinoma cervix , cancer judgment investigator sponsor may affect interpretation result ( example , prostate , bladder ) . History interstitial lung disease active noninfectious pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>